IL6 and chronic obstructive pulmonary disease: The use of monoclonal anti-IL-6 antibody to block IL-6 can significantly reduce the promoting effect of COPD-like airway inflammation on lung tumor cell proliferation and tumor angiogenesis and bias the precursor immunosuppressive environment to anti-tumor phenotype, indicating that IL-6 is a potential drug target for the prevention and treatment of K-ras-mutant lung tumors.